Ichnos Sciences, a wholly-owned subsidiary of Glenmark Pharmaceuticals, on Thursday announced that the company has entered into an exclusive worldwide licensing agreement for its OX40 antagonist monoclonal antibody portfolio with Astria Therapeutics, a biopharmaceutical company developing therapies for rare allergic and immunological diseases.
With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company’s prioritisation of its pipeline of oncology drug candidates, the company said in a press statement.
Within the terms of the agreement, Astria will assume full cost and responsibility for the global development and commercialisation of the licensed therapeutic program for all indications, it added. “In exchange, Ichnos will receive up to $320 million in upfront, development, regulatory and sales milestone payments in addition to up to low double-digit royalties. Ichnos has also agreed to allow Astria to draw down on its existing investigational drug substance and drug product stocks at normalised costs to facilitate development,” the company stated.
According to a press statement, Telazorlimab is a novel, humanized IgG1 monoclonal antibody that targets OX40 on T-cells responsible for inflammation and immunity diseases. “Excessive OX40 signaling, expressed on activated T cells, is the feature of several inflammatory diseases, including atopic dermatitis (AD),” it added.
“As Ichnos continues to grow as a biotechnology company, this agreement enables our team to focus on advancing our robust pipeline of clinical-stage multispecific antibodies in oncology generated by our proprietary BEAT platformi, as well as continue the discovery and development of our NK-cell engaging programs for solid tumors,” said Cyril Konto, M.D., President and CEO of Ichnos. “I am proud of the work achieved by the Ichnos team in successfully completing the Phase 2b with telazorlimab in atopic dermatitis and potentially opening up a new therapeutic class for this disease. Ichnos is confident in Astria Therapeutics’ capabilities and vision for pursuing the development of its OX40 program and delivering a potentially life-changing treatment to patients with inflammatory and immune diseases.”
Astria plans to develop an affinity-matured version of telazorlimab and apply YTE half-life extension technology to create a product that aims to address the need for a safe, effective, and infrequently administered AD treatment, it added.
“We are looking forward to building on the foundational work that Ichnos has done with their OX40 portfolio,” said Jill Milne, Ph.D., co-founder and CEO of Astria Therapeutics. “We believe that by using Ichnos’ affinity-matured next-generation monoclonal antibody OX40 antagonist and applying YTE half-life extension technology, we have the potential to deliver a best-in-class profile for atopic dermatitis patients; one that we think can be safe, effective, and long-acting. In addition to OX40 antagonism already being a clinically validated mechanism in atopic dermatitis, we also are excited about the opportunity for potential expansion into additional indications.”
